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Abstract 
The number of new psychoactive substances keeps on rising despite the controlling efforts by 
law enforcement. Although metabolism of the newly emerging drugs is continuously studied 
to keep up with the new additions, the exact structures of the metabolites are often not identified 
due to the insufficient sample quantities for techniques such as nuclear magnetic resonance 
(NMR) spectroscopy. The aim of the study was to characterise several metabolites of the 
synthetic cannabinoid (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 
(UR-144) by NMR spectroscopy after the incubation with the fungus Cunninghamella elegans. 
UR-144 was incubated with C. elegans for 72 h and the resulting metabolites were 
chromatographically separated. Six fractions were collected and analysed by NMR 
spectroscopy. UR-144 was also incubated with human liver microsomes (HLM), and the liquid 
chromatography–high resolution mass spectrometry analysis was performed on the HLM 
metabolites with the characterised fungal metabolites as reference standards. Ten metabolites 
were characterised by NMR analysis including dihydroxy metabolites, carboxy and hydroxy 
metabolites, a hydroxy and ketone metabolite, and a carboxy and ketone metabolite. Of these 
metabolites, dihydroxy metabolite, carboxy and hydroxy metabolites, and a hydroxy and 
ketone metabolite were identified in HLM incubation. The results indicate that the fungus is 
capable of producing human-relevant metabolites including the exact isomers. The capacity of 
the fungus C. elegans to allow for NMR structural characterisation by enabling production of 
large amounts of metabolites makes it an ideal model to complement metabolism studies. 
 
KEY WORDS: Synthetic cannabinoid, Metabolism, Cunninghamella elegans, UR-144, NMR 
 
Abbreviations 
C. elegans Cunninghamella elegans
ESI Electrospray ionisation source 
gCOSY Gradient correlation spectroscopy 
gHMBC Gradient heteronuclear multiple bond 
correlation 
gHSQC Gradient heteronuclear single quantum 
correlation 
HLM Human liver microsomes 
HPLC High-performance liquid chromatography 
LC-QTOF-MS Liquid chromatography-quadrupole time-of-
flight mass spectrometry 
MS Mass spectrometry 
NOESY Nuclear Overhauser effect spectroscopy 
NMR Nuclear magnetic resonance 
NPS New psychoactive substances 
TMCP Tetramethylcyclopropyl 
UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone 
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Introduction 
The emergence of new psychoactive substances (NPS) has been a worldwide problem for the 
last decade. In 2016, the rate of the emergence of new drugs has slowed down according to the 
European Monitoring Centre for Drugs and Drug Addiction [1]. The reporting of 66 new drugs 
in Europe during the year was the fewest within the last 5 years. Nevertheless, the introduction 
of more than 1 drug per week still poses a significant challenge especially when more than 620 
NPS have to be monitored. 
In an effort to keep up with the detection of NPS in drug testing, a number of metabolite 
identification studies have been conducted [2-6]. This is particularly important for drugs that 
are extensively metabolised such as synthetic cannabinoids, as the parent drugs may not be 
present in urine, giving a false negative result [7]. Identification of metabolites can also 
contribute to the more comprehensive determination of the drug safety, since some metabolites 
can retain significant pharmacological activities, complicating the adverse effects of the drugs 
[8]. 
Several in vivo and in vitro models are commonly used to identify metabolic profiles. Among 
the in vivo models, controlled self-administration of drugs is a rare strategy due to the health 
risks and ethical concerns, although it naturally gives the most reliable data [9]. Other in vivo 
models involve the use of animals such as rats and mice. These models offer the advantage of 
metabolism occurring within whole animal organisms similar to the human body, although they 
can be expensive and ethically undesirable, in addition to species differences [6, 10]. The most 
common in vitro model is human liver microsomes (HLM), which are relatively cheap and 
relevant to human metabolism. However, the lack of some enzymes present in cells can limit 
the ability to produce relevant in vivo metabolites including phase II metabolites. Also, the 
typical reaction condition, which contains excessive oxygen, may limit reductive 
transformation pathways, even when HLM has the appropriate enzyme for the reaction [6]. In 
contrast, human primary hepatocytes generally provide metabolite profiles that resemble in 
vivo human profiles more closely, as they are living cells with a closer environment to the 
human body than enzymes [11]. 
Although the aforementioned models provide invaluable metabolic data, they have one 
common limitation: production of small amounts of metabolites. With the recent advances in 
sensitivity of mass spectrometric techniques, the amounts obtained with these models generally 
suffice for mass spectrometric analysis. However, mass spectrometric analysis alone is often 
not adequate for unequivocal structural elucidation including the exact positions of 
modifications made, leading to the need for analysis by other techniques such as nuclear 
magnetic resonance (NMR) spectroscopy [11]. Unfortunately, NMR spectroscopy is still a 
relatively insensitive technique, for which the amount of metabolites obtained from the 
common models is usually insufficient. Therefore, currently for the unambiguous 
characterisation of metabolites using these models, it is vital to use reference standards to 
compare the retention time and mass fragmentation pattern in mass spectrometry. 
The fungus Cunninghamella elegans (C. elegans) has been investigated for its capability to 
mimic human metabolism for decades and is suggested to provide the solution for producing 
sufficient quantities of metabolites [10]. C. elegans can produce a wide variety of metabolites 
in a similar manner to humans and incubation of C. elegans culture can easily be upscaled, 
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allowing large production of metabolites. The advantage of large quantities of metabolites 
obtained from C. elegans has been proven useful in studies reporting structural characterisation 
of metabolites using NMR spectroscopy [12, 13]. We have previously demonstrated, using 
liquid chromatography – high resolution mass spectrometry, that C. elegans incubation of 
synthetic cannabinoids, including (1-pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone (UR-144), can result in similar metabolic profiles to human 
metabolism [14, 15]. 
In this paper, we report, for the first time using NMR spectroscopy, the structural elucidation 
of several metabolites of UR-144, which was among the five most commonly seized synthetic 
cannabinoids in Europe in 2015 [1]. UR-144 was also incubated with HLM and the 
characterised fungal metabolites were used as reference standards to determine whether these 
fungal metabolites are produced in HLM incubation. 
 
Materials and methods 
Chemicals and reagents 
UR-144 was synthesised in-house following previously reported methods and characterised by 
mass spectrometry (MS) and 1D, 2D NMR spectroscopy [16, 17]. LC-MS grade acetonitrile 
was obtained from Honeywell (Muskegon, MI, USA). Reagent grade dichloromethane and 
sodium chloride were from Chemsupply (Gilman, SA, Australia). LC-MS grade formic acid 
and deuterated chloroform (99.8 atom % D, containing 0.03 % (V/V) TMS) was purchased 
from Sigma–Aldrich (St. Louis, MO, USA). C. elegans ATCC 10028b was from Cryosite Ltd. 
(South Granville, NSW, Australia). Glycerol and potassium dihydrogen phosphate and 
dipotassium hydrogen phosphate were obtained from Ajax Chemicals (Auburn, NSW, 
Australia). Potato dextrose agar, glucose, peptone, and yeast extract were purchased from 
Oxoid Australia (Adelaide, SA, Australia). HLM 50-Doner pool, NADPH system solution A 
and NADPH system solution B were obtained from Corning (Corning, NY, USA). 
 
Fungus metabolite characterisation 
Fungus incubation 
Incubation of UR-144 with C. elegans was performed as described in the previous study [14], 
with the following deviations. A total of 5 L growth media in multiple conical flasks were used 
to incubate 50 mg of UR-144. Following liquid-liquid extraction using dichloromethane, the 
combined extracts were evaporated to dryness and reconstituted in 14 mL of water:acetonitrile 
(55:45, v/v). 
 
Preparative high-performance liquid chromatography (HPLC) 
HPLC system consisted of an Agilent 1290 LC system with an Agilent Zorbax Eclipse XDB-
C18 semi-preparative column (250 mm × 9.4 mm, 5 μm) and an Agilent 1260 Infinity diode 
array detector. A hundred microlitre of the sample was injected into HPLC to separate some 
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UR-144 metabolites, and six fractions were collected, after diode array detection at 254 nm, to 
obtain purified metabolites. The mobile phase consisted of 0.1% formic acid in water (A) and 
0.1% formic acid in acetonitrile (B) at a flow rate of 4.0 mL/min. A run was performed over 
18 min in gradient mode with 45% B from 0 to 10 min, ramped to 95% B at 11 min and held 
till 14 min, and ramped back to 45% B at 15 min and held till 18 min. The column temperature 
was kept at 30°C. The procedure was repeated 100 times to obtain sufficient amount of 
metabolites for NMR analysis. The fractions were placed under a gentle stream of nitrogen gas 
to remove acetonitrile and then freeze-dried. The samples were redissolved in CDCl3 and 
analysed by NMR. 
 
NMR spectroscopy 
NMR spectra were acquired at room temperature on an Agilent 500 MHz NMR spectrometer 
coupled with an Agilent 7510-AS automated NMR sample changer. UR-144 and its 
metabolites were characterised by 1H NMR, 13C NMR, gradient correlation spectroscopy 
(gCOSY), gradient heteronuclear single quantum correlation (gHSQC), gradient heteronuclear 
multiple bond correlation (gHMBC, jnxh = 8 Hz), and nuclear Overhauser effect spectroscopy 
(NOESY) experiments. Acquisition was performed at the frequency of 499.86 and 125.70 MHz 
for 1H and 13C NMR, respectively. Chemical shifts are reported in δ (ppm) and were measured 
relative to CDCl3 (1H δ = 7.26, 13C δ = 77.0). 
 
Liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) 
Each metabolite isolated by preparative HPLC was analysed by LC-QTOF-MS in the same 
manner as described in the previous study [14], to confirm the identity of the metabolites and 
compare with the results in the study. 
 
HLM metabolite characterisation 
HLM incubation  
UR-144 solution in acetonitrile:water (40:60 v/v, 1 mg/mL, 25 µL), phosphate buffer (0.1M, 
pH7.4, 855 µL), NADPH-A (50 µL) and NADPH-B (20 µL) were mixed in an Eppendorf tube, 
to which HLM (50 µL) was added. The final concentration of acetonitrile was 1%. The mixture 
was incubated at 37 °C in a shaking water bath for 3 h. Ice-cold acetonitrile (1 mL) was added 
to the mixture for quenching and the Eppendorf tube was centrifuged at 16,060×g for 10 min. 
The supernatant was filtered with a 0.22 µm filter. Two microlitre was injected into LC-QTOF-
MS. A degradation control sample without HLM and a control without UR-144 were also 
incubated and analysed. 
 
LC-QTOF-MS 
LC-QTOF-MS experiments were performed as described above with the following exceptions. 
Some analyses were performed on an Agilent 6550A iFunnel Q-TOF with a Dual AJS ESI 
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source in Auto MSMS mode, operated with the same parameters as for the fungus analysis 
except for the following: gas temperature, 290 °C; gas flow, 11 L/min; sheath gas temperature, 
350 °C; sheath gas flow, 11 L/min; max precursors per cycle, 5; static exclusion ranges, 100-
300 and 500-1000. 
 
Results 
Fungus metabolite characterisation 
After incubation of UR-144 with C. elegans, the metabolites were separated by HPLC. Based 
on the abundance and separation of the peaks, six fractions (labelled as fraction 1– fraction 6 
below) containing one peak each were isolated and collected for further analysis, apart from 
fractions 2 and 3 where two peaks partially coeluted and could not be completely separated 
(Fig. 1). LC-QTOF-MS analysis revealed that fraction 1 gave rise to a single peak which was 
labelled as U7 in our previous study [14], attributing to metabolite(s) of dihydroxylation. Under 
the analytical conditions employed for LC-QTOF-MS analysis, the peaks in fractions 2 and 3 
eluted as a single peak (U10) corresponding to metabolite(s) with carboxylation and 
hydroxylation. Fraction 4 was a metabolite with hydroxylation and ketone formation (U14). 
Fraction 5 corresponded to U15, another metabolite with carboxylation and hydroxylation. 
Fraction 6 was a metabolite with carboxylation and ketone formation (U17). 
 
NMR analysis 
In total, 10 metabolites were characterised by NMR from six fractions as shown in Fig. 2 
(fraction 1 contained M1-M3 (U7); fraction 2, M4 (U10); fraction 3, M5, M6 (U10); fraction 
4, M7 (U14); fraction 5, M8, M9 (U15); fraction 6, M10 (U17)). The assigned 1H and 13C NMR 
data of UR-144 and the metabolites are presented in Tables I - III. The gCOSY and gHMBC 
correlations, and selected NOE correlations are depicted in Fig. 3 and were used to aid 
assignment of some overlapped 1H and 13C NMR signals in Tables I-III.  
 
HLM metabolite characterisation 
Based on the comparison of retention time and fragmentation pattern in MSMS scan with the 
fungal metabolites, dihydroxy metabolite (U7), carboxy and hydroxy metabolites (U10 and 
U15), and hydroxy and ketone metabolite (U14) were identified after HLM incubation. 
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Discussion 
Fungus metabolite characterisation 
According to the LC-QTOF-MS analysis in MSMS mode, the following metabolites were 
identified: dihydroxy metabolite(s) (U7) in fraction 1, carboxylation and hydroxylation 
metabolites (U10) in fractions 2 and 3 and (U15) in fraction 5, a hydroxylation and ketone 
formation metabolite (U14) in fraction 4, and a carboxylation and ketone formation metabolite 
(U17) in fraction 6. To determine the exact positions of the modifications in these metabolites, 
1D and 2D NMR data was obtained including 1H, 13C, gCOSY, gHSQC, gHMBC, and NOESY 
spectra. 
 
NMR analysis 
UR-144 
First, the parent drug UR-144 was analysed (Table I). NMR data of UR-144 have been 
previously reported with some discrepancies in signal assignments among the studies [18-20]. 
Our results agree well with the assignments given by Langer et al. [18]. After the analysis of 
UR-144, each fraction containing metabolites was analysed. Since all the metabolites were 
determined to have the intact indole moiety based on LC-QTOF-MS, the signals related to the 
indole moiety are generally not discussed below. 
 
Dihydroxy metabolites M1-M3 (U7) 
LC-QTOF-MS analysis of fraction 1 (U7) tentatively assigned the single peak (RT = 6.9 min, 
Fig. 1) as dihydroxy metabolite(s), with one hydroxy group located at the 
tetramethylcyclopropyl (TMCP) ring and the other one at the pentyl side chain, as reported in 
the previous study [14]. NMR study has shown that this fraction in fact contained three isomers 
designated as M1, M2, and M3, respectively (Table I). The NMR data shows that hydroxylation 
at the TMCP ring occurred at one of the four methyl groups instead of the C-1''' adjacent to the 
carbonyl group. This assignment was based on two observations. Firstly, the C-1''' was found 
to retain its hydrogen resonating around δ 2.12 ppm. Secondly, the appearance of the signals 
at δ 3.77 ppm as a doublet of doublets was attributable to the diastereotopic methylene protons 
following hydroxylation at one of the four methyl groups (2'''-Me, or 3'''-Me); the strong shift 
of the signal from around δ 1.30 ppm to the low magnetic field by approximately δ 2.45 ppm 
is in line with the electron withdrawing effect of the added hydroxyl group. NOESY cross 
peaks at δ 2.12-2.13 (H-1''')/δ 3.77 (HO-CH2-(E)-2''') and δ 2.12-2.13 (H-1''')/δ 1.36-1.39 (CH3-
(E)-3''') suggests that the metabolites are E-isomers in that the hydroxy group is in an 
orientation trans to the adjacent carbonyl group (Fig. 3, M1-M3). Based on the results, the 
hydroxy group can be either at (E)-2'''-Me or (E)-3'''-Me. For simplicity, the hydroxy group is 
shown at (E)-2'''-Me only, as the ring structure is otherwise symmetrical. Similarly, 
hydroxylation and carboxylation for the subsequent metabolites will also be shown at 2'''-Me 
only rather than 2'''-Me and 3'''-Me.  
In contrast to the TMCP ring, hydroxylation at the pentyl side chain occurred at two different 
positions. COSY and HMBC correlations showed two spin systems for the side chain as shown 
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in Fig. 3 (M1-M3). One of them is a 5-hydroxypentyl metabolite (M1), which is supported by 
C-5'' having two hydrogens instead of three as indicated by an HSQC cross peak (data not 
shown). The other one is a 4-hydroxypentyl metabolite, which is supported by H-5'' being a 
doublet. While 5-hydroxypentyl chain is achiral, 4-hydroxypentyl chain has a chiral centre. 
Therefore, 4-hydroxypentyl chain can exist as enantiomers with C-4'' having (R) or (S) 
configuration. In addition, the hydroxylated TMCP ring determined above also has a chiral 
carbon at (E)-2''' when (E)-2'''-Me is hydroxylated, i.e. (S)-isomer, whereas the metabolite with 
a hydroxy group at (E)-3'''-Me has the (R) configuration. Hence, there can be four stereoisomers 
for the dihydroxy metabolites containing 4-hydroxypentyl chain and a hydroxy group at (E)-
2'''-Me or (E)-3'''-Me. Of the four stereoisomers, (4''R, 3'''R) and (4''S, 2'''S) are enantiomers as 
well as (4''R, 2'''S) and (4''S, 3'''R). Since enantiomers are not differentiated by NMR spectra, 
only the two diastereomers should appear in the spectra as observed in the study (M2 and M3). 
All three metabolites are similar in structure and account for the coelution in LC separation. 
 
Hydroxy and ketone metabolite M7 (U14) 
Fraction 4 (M7) showed proton and carbon signals almost identical to M2 and M3 for the 
TMCP ring indicating hydroxylation at (E)-2'''-Me (Table III). The distinct carbon signal at δ 
207.5 ppm suggested the presence of a ketone group, which is consistent with the MS findings. 
The proton signals for the pentyl side chain showed one singlet, two triplets and one quintet. A 
singlet can occur only when C-2'' or C-4'' has a ketone group. If C-2'' had a ketone group, H-1'' 
would become a singlet. However, there was a triplet at δ 4.21ppm corresponding to H-1'' as 
seen for UR-144 and the dihydroxy metabolites, which concludes the position of the ketone 
group to be at C-4'' of the pentyl side chain. The cross peaks in COSY and HMBC also 
supported the location of the ketone group to be C-4'' (Fig. 3). The metabolite M7 is an oxidised 
metabolite of M2 and/or M3 (Fig. 2). 
 
Carboxy and hydroxy metabolites M4-M6 (U10) and M8-M9 (U15) 
Since fractions 2 and 3 were collected from the coeluting peaks in preparative HPLC, these 
fractions were expected to contain a few metabolites originating from the two coeluting peaks. 
Indeed, they contained signals from both peaks, but the relative abundance of the signals made 
it clear enough for assigning which signals were from fraction 2 or fraction 3. As expected 
from MS analysis, fraction 2 (M4) showed a carbon signal at δ 173.6 ppm for carboxylic acid 
in the TMCP ring (Table II). Based on the structure of the TMCP ring, the possible position 
for carboxylation is at one of the four methyl groups, i.e., 2'''-Me or 3'''-Me. NOESY cross 
peaks at δ 2.38 (H-1''')/δ 1.56 (CH3-(E)-2''') and δ 2.38 (H-1''')/δ 1.50 (CH3-(E)-3''') indicated 
that the carboxy group is cis to the carbonyl group (Fig. 3). The hydroxy group at the pentyl 
side chain was assigned at H-5'' based on the COSY and HMBC data (Fig. 3). The proton and 
carbon data for the side chain was analogous to those of M1, as M1 is also hydroxylated at H-
5''. 
Having coeluted with a peak in fraction 2, a peak in fraction 3 is expected to have structurally 
similar compounds. In fact, fraction 1 displayed a similar case where 5-hydroxypentyl 
metabolite with another hydroxy group at the TMCP ring coeluted with two diastereomers of 
4-hydroxypentyl metabolites having another hydroxy group at the TMCP ring. As expected, 
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fraction 3 showed the presence of 4-hydroxypentyl metabolite with a carboxy group at the 
TMCP ring (M5 and M6); the carboxy group was found cis to the carbonyl group in the TMCP 
ring as indicated by NOSEY cross peaks at δ 2.38 (H-1''')/δ 1.56 (CH3-(E)-2''') and δ 2.38 (H-
1''')/δ 1.50 (CH3-(E)-3'''), and the hydroxy group was assigned to H-4'' by COSY and HMBC 
cross peaks (Fig. 3), and the proton and carbon data was similar to that of M2 and M3. As was 
the case with M2 and M3, M5 and M6 can have two diastereomers due to the presence of two 
stereo centres, and hence H-2' and some carbon atoms showed two signals corresponding to 
the presence of diastereomers. 
Fraction 5 (M8 and M9) showed the proton and carbon signals for the TMCP ring, almost 
identical to those of M4-M6, indicating the carboxy group is cis to the carbonyl group (Table 
II, Fig. 3). Now that M4, and M5 and M6 were characterised as 5-hydroxypentyl and 4-
hydroxypentyl metabolites, respectively, the position of the hydroxy group in the pentyl side 
chain for this fraction can only be at H-1'', H-2'' or H-3''. Regardless of the exact position, the 
metabolite would have two stereo centres, leading to two diastereomers as described above. 
Indeed, H-2' showed two signals resulting from the diastereomers. The cross peaks in COSY 
and HMBC revealed the position of hydroxylation to be at H-3'', which is supported by the fact 
that the proton peak at δ 4.42 (H-1'') is a triplet, which would be a doublet for a 2-hydroxypentyl 
metabolite, and the peak has two protons according to the HSQC data and hence cannot be 
hydroxylated at H-1''. 
 
Carboxy and ketone metabolite M10 (U17) 
Fraction 6 (M10) showed similar proton, carbon and 2D NMR data to M4, M5, M6, M8, and 
M9 for the TMCP ring, indicating carboxylation at a methyl group cis to the carbonyl group 
(Table III, Fig. 3). For the pentyl side chain, the ketone carbon signal at δ 207.2 ppm together 
with proton and carbon data similar to M7 allowed the position of ketone formation to be C-
4''. This metabolite M10 is considered to be derived from further oxidation of M5 and/or M6 
(Fig. 2). It is interesting to note that the chemical shift of carbon signals at C-4', C-5' and C-6' 
in the indole moiety were in the order of C-4' < C-5' < C-6' for M10 and all the other metabolites 
with a carboxy group at the TMCP ring, whereas it was in the order of C-5' < C-4' < C-6' for 
UR-144 and the other metabolites. 
 
HLM metabolite characterisation 
Using the isolated and characterised fungal metabolites as reference standards, dihydroxy 
metabolite (U7/M1-M3), carboxy and hydroxy metabolites (U10/M4-M6 and U15/M8-M9), 
and hydroxy and ketone metabolite (U14/M7) were able to be identified in the HLM sample. 
Under the chromatographic conditions employed, 5-hydroxypentyl and 4-hydroxypentyl 
metabolites (M1-M3 and M4-M6) coeluted, and hence, there can be both or either of the 
metabolites. The presence of these metabolites was previously reported in human metabolism 
as well as the fungal metabolism: dihydroxy metabolites and hydroxy and ketone metabolites 
in human urine; dihydroxy metabolites and carboxy and hydroxy metabolites in HLM; all the 
metabolites in the fungus [14, 21-24]. However, it was not possible to determine if the human 
metabolites were the same as the exact isomers found in the fungus without analysing them by 
the same LC-MS system. Given that the exact isomers of the fungal metabolites were identified 
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after HLM incubation, the fungal metabolites can be a powerful tool to characterise human 
metabolites. 
 
Advantages and disadvantages of the fungus metabolism 
The main advantage of the fungus C. elegans is that experiments can easily be upscaled, which 
would allow NMR analysis of metabolites. As mentioned before, the NMR analysis of 
metabolites is imperative for comprehensive characterisation of most metabolites without using 
reference standards. This proves even more important for the metabolites which are not 
commercially available. As of now, there are only six metabolites available for UR-144 from 
Cayman Chemical: N-pentanoic acid metabolite, N-(5-hydroxypentyl) metabolite, (±)-N-(4-
hydroxypentyl) metabolite, N-(2-hydroxypentyl) metabolite, N-(5-hydroxypentyl) β-D-
glucuronide, and UR-144 degradant N-pentanoic acid metabolite [25]. Also, the present study 
has demonstrated that NMR analysis can detect two or more isomers, which cannot be 
differentiated by MS, in a reasonably symmetrical peak in a chromatogram. Therefore, to fully 
characterise other metabolites including M1-M10, analysis by NMR spectroscopy is essential, 
and this could be provided by a large-scale fungus experiment. The limitations of the large-
scale fungus experiment include the difficulty in separating closely structured isomers using 
preparative HPLC, and the amounts of metabolites obtained are still generally less than those 
obtained by synthesis, making the NMR interpretation more challenging. However, 
chromatographic separations may be significantly improved by the use of different HPLC 
columns such as chiral columns, and a larger column will make it easier to obtain larger 
amounts of metabolites. Unlike organic synthesis, several metabolites can be obtained in one 
incubation, in which the fungus “synthesises” the metabolites for us, including the metabolites 
which are difficult to synthesise chemically [10]. Hence, the fungus C. elegans can be an 
invaluable model for studying drug metabolism. 
 
Conclusion 
The synthetic cannabinoid UR-144 was incubated with the fungus C. elegans in a large scale, 
and several metabolites were isolated by preparative HPLC. Ten metabolites were 
characterised by NMR analysis, including dihydroxy metabolites, carboxy and hydroxy 
metabolites, a hydroxy and ketone metabolite, and a carboxy and ketone metabolite. UR-144 
was also incubated with HLM, and the characterised fungal metabolites were used as reference 
standards to determine if these metabolites were generated by HLM. LC-QTOF-MS analysis 
identified dihydroxy metabolite (U7), carboxy and hydroxy metabolites (U10 and U15), and 
hydroxy and ketone metabolite (U14) after HLM incubation. These findings demonstrate the 
ability of the fungus to produce human-relevant metabolites of the synthetic cannabinoid in 
sufficient abundance for NMR analysis, indicating the potential for the fungus model as a tool 
to complement metabolism studies. 
The study highlights the limitations of LC-MS/MS in identifying metabolites of NPS, an 
analytical technique widely utilised in carrying out metabolism study. It also illustrates the 
importance of using other complimentary techniques such as NMR in unambiguous elucidation 
of metabolite structures. 
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Figures 
 
Fig. 1. Preparative HPLC chromatogram showing separation of fractions 1–6. Fractions 2 and 
3 partially coeluted. Summarised here are also the corresponding metabolites identified by 
NMR and LC-MS/MS in each fraction. 
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Fig. 2. The structures of UR-144 and the metabolites analysed in this study. Brackets indicate 
the metabolite ID in our previous paper [14]. Arrows indicate partial metabolic pathways. M2 
and M3, M5 and M6, and M8 and M9 are diastereomers, respectively, and share the same 
structures apart from the spatial configurations at the stereo centres 
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Fig. 3. Gradient correlation spectroscopy (gCOSY), gradient heteronuclear multiple bond 
correlation (gHMBC), and selected nuclear Overhauser effect (NOE) correlations of UR-144 
and the metabolites analysed in the study 
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Tables 
Table I. 1H and 13C NMR data for UR-144 and fraction 1 containing dihydroxy metabolites 
(M1-M3) in CDCl3 
Position 
No. 
UR-144 Fraction 1 
M1 M2/M3 M1 M2/M3 
13C 1H 13C 1H 
1 194.6  193.4  
2' 133.4 7.66 (s) 134.0 134.1, 
134.4 
7.83 (s) 7.87 (s), 7.88 
(s) 
3' 119.6  119.1, 119.2  
3'a 126.4 126.38, 126.42 
4' 122.7 8.39-8.41 (m) 122.7 8.38-8.40 (m) 
5' 122.0 7.23-7.29 (m), 
overlapped 
122.26, 122.28 7.24-7.30 (m), overlapped 
6' 122.8 7.23-7.29 (m), 
overlapped 
123.0, 123.1 7.24-7.30 (m), overlapped 
7' 109.6 7.33-7.35 (m) 109.60, 109.63 7.33-7.37 (m) 
7'a 136.6 136.6 
1'' 47.0 4.14 (t, J = 7.3 
Hz) 
46.9 46.8 4.20 (t, J = 
7.0 Hz) 
4.20 (t, J = 
7.0 Hz) 
2'' 29.6 1.89 (quintet, J= 
7.5 Hz)) 
29.5 26.1, 
26.2 
1.93a, 
overlapped 
1.90-2.10 
(m) 
3'' 29.0 1.36a, 
overlapped 
23.2 35.9, 
36.0 
1.44a, 
overlapped 
1.49 (quintet, 
J = 7.3 Hz) 
4'' 22.2 1.36a, 
overlapped 
31.9 67.6, 
67.7 
1.61a, 
overlapped 
3.84 (m), 
overlapped 
5'' 13.9 0.91 (t, J = 7.0 
Hz) 
62.5 23.8, 
23.9 
3.65 (td, J = 
6.3, 4.3 Hz) 
1.20 (d, 6.0 
Hz) 
1''' 41.6 1.94 (s) 38.76, 38.77 2.120 (s), 2.124 (s), 2.13 (s) 
2''' 31.5 36.0, 36.1 
3''' 31.5 30.0, 30.1, 30.2 
(E)-2'''-Me 24.0 1.31 (s) 69.3, 69.4, 69.5 3.766 (dd, J 
= 36.3, 11.3 
Hz) 
3.765 (dd, J 
= 19.5, 11.5 
Hz), 3.769 
(dd, J = 28.8, 
11.3 Hz)  
(Z)-2'''-Me 17.0 1.35 (s) 12.4, 12.5 1.40 (s), 1.42 (s), 1.43 (s) 
(E)-3'''-Me 24.0 1.31 (s) 17.52, 17.55, 
17.57, or 23.5b 
1.36 (s), 1.37 (s), 1.378 (s), 
1.380 (s), 1.384 (s), 1.39 (s), 
overlapped 
(Z)-3'''-Me 17.0 1.35 (s) 17.52, 17.55, 
17.57, or 23.5b 
1.36 (s), 1.37 (s), 1.378 (s), 
1.380 (s), 1.384 (s), 1.39 (s), 
overlapped 
a The chemical shifts were taken from HSQC data 
b Based on the data, it could not be determined which chemical shifts correspond to (E)- and 
(Z)-methyl carbons 
17 
 
Table II. 1H and 13C NMR data for carboxy and hydroxy metabolites (M4–6 and M8–9) in 
CDCl3 
Position 
No. 
M4 M5/6 M8/9  
 13C 1H 13C 1H 13C 1H 
1 196.4 196.4 ND  
2' 136.2 7.80 (s) 136.3 7.82 (s), 7.83 
(s) 
136.8 7.85 (s), 7.88 
(s) 
3' 117.2 117.1b 117.2b  
3'a 126.1 126.1 126.1b  
4' 122.7 8.32-8.34 (m) 122.7 8.32-8.34 (m) 122.7 8.32-8.34 (m) 
5' 123.7 7.35-7.38 
(m), 
overlapped 
123.7 7.35-7.38 
(m), 
overlapped 
123.7 7.35-7.38 
(m), 
overlapped 
6' 124.1 7.35-7.38 
(m), 
overlapped 
124.1 7.35-7.38 
(m), 
overlapped 
124.1 7.35-7.38 
(m), 
overlapped 
7' 110.2 7.40-7.44 (m) 110.3 7.40-7.44 (m) 110.3 7.45-7.47 (m) 
7'a 136.9 136.9 136.9b 
1'' 47.5 4.24 (td, J = 
7.1, 3.8 Hz) 
47.5 4.28 (t, J 
=7.3) 
44.3 4.42 (t, J = 
8.3 Hz) 
2'' 29.6 1.98 (quintet, 
7.5 Hz) 
26.2, 
26.3 
1.96-2.14 (m) 36.2 1.86-1.94 
(m), 2.06-
2.14 (m) 
3'' 23.2 1.48a, 
overlapped 
35.69, 
35.72 
1.51a, 
overlapped 
70.0 3.46-3.52 (m) 
4'' 31.9 1.63a, 
overlapped 
67.5, 
67.6 
3.85-3.90 (m) 30.8 1.52a, 
overlapped 
5'' 62.3 3.67 (t, 6.3 
Hz) 
24.0, 
24.1 
1.22 (d, J = 6 
Hz) 
9.7 0.94 (t, J = 
7.5 Hz) 
1''' 44.0 2.38 (s) 44.0 2.38 (s) 44.0 2.38 (s) 
2''' 40.4 40.4 40.4b 
3''' 33.2 33.2 33.2b 
(E)-2'''-Me 21.1 1.56 (s) 21.1 1.56 (s) 21.1 1.56a, 
overlapped 
(Z)-2'''-Me 173.6 173.6 173.6b 
(E)-3'''-Me 22.3 1.50 (s) 22.26, 
22.29 
1.50 (s) 22.3 1.49 (s) 
(Z)-3'''-Me 17.6 1.26 (s) 17.61, 
17.62 
1.26 (s) 17.6 1.26 (s) 
ND not detected 
a The chemical shifts were taken from HSQC data 
b The chemical shifts were taken from HMBC data 
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Table III. 1H and 13C NMR data for a hydroxy and ketone metabolite (M7) and a carboxy 
and ketone metabolite (M10) in CDCl3 
Position 
No. 
M7  M10 
 13C 1H 13C 1H 
1 193.4  ND 
2' 133.9 7.78 (s) 136.2 7.79 (s) 
3' 119.4  117.4b 
3'a 126.3  126.0 
4' 122.8 8.38-8.40 (m) 122.7 8.32-8.34 (m) 
5' 122.4 7.26-7.30 (m), 
overlapped 
123.7 7.35-7.39 (m), 
overlapped 
6' 123.2 7.26-7.30 (m), 
overlapped 
124.3 7.35-7.39 (m), 
overlapped 
7' 109.6 7.35-7.37 (m) 110.3 7.44-7.47 (m) 
7'a 136.6 136.9b 
1'' 45.7 4.21 (t, J =7.3 Hz) 46.3 4.27 (t, J = 7.3 Hz) 
2'' 23.8 2.17 (quintet, J = 6.9 
Hz) 
23.8 2.19 (quintet, J = 6.9 
Hz) 
3'' 39.6 2.43 (t, J = 6.8 Hz) 39.4 2.49 (td, J = 6.4, 2.8 
Hz) 
4'' 207.5 207.2 
5'' 30.0 2.11 (s), overlapped 30.1 2.15 (s) 
1''' 38.8 2.11 (s), overlapped 44.0 2.37 (s) 
2''' 36.3 40.5b 
3''' 30.4  33.4 
(E)-2'''-Me 69.5 3.77 (dd, J = 38.0, 
11.0 Hz) 
21.1 1.57c, overlapped 
(Z)-2'''-Me 12.4 1.44 (s) 173.5b 
(E)-3'''-Me 17.5 or 
23.5a 
1.38 (s), overlapped 22.3 1.50 (s) 
(Z)-3'''-Me 1.38 (s), overlapped 17.6 1.26 (s) 
ND not detected 
a Based on the data, it could not be determined which chemical shifts correspond to (E)- and 
(Z)-methyl carbons 
b The chemical shifts were taken from HMBC data 
c The chemical shifts were taken from HSQC data 
 
 
